4 gene therapy trials showing curative potential for hepatic copper in 2026
As 2026 begins, the global hepatology community is closely monitoring a wave of breakthrough data from Phase II and III trials that aim to permanently correct the ATP7B genetic mutation. Regulatory authorities in the European Union and the United States have recently signaled a willingness to accept biomarker-driven endpoints, such as long-term reduction in non-ceruloplasmin bound copper, to...
0 Yorumlar
0 hisse senetleri
166 Views